Rx Drug Promotion Risks: Value Claims, Getting Close To Patients
Executive Summary
Comparative claims to distinguish a product are triggering FDA enforcement letters; companies also face risks when interacting more with patients.
You may also be interested in...
Website “Influence” Shouldn’t Make Firms Responsible For Content – PhRMA
FDA’s social media guidance on interactive promotional materials should require companies to submit only content that they have control over, PhRMA and BIO tell FDA; industry asks for clarification on a firm’s responsibility for user-generated content, such as comments on off-label use.
FDA’s Social Media Guidance Gives Firms A Pass On User-Generated Content
The draft guidance outlines substantial reporting requirements for websites that firms control and for content on third-party sites – as well as saying when FDA intends to use enforcement discretion.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.